Antiviral discovery for highly pathogenic emerging viruses / edited by César Muñoz-Fontela and Rafael Delgado
New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state of the art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents. Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field.
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
[2022] © 2022 |
|---|---|
| Erschienen: |
Cambridge: Royal Society of Chemistry ; 2022 © 2022 |
| Reihe: |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Muñoz-Fontela, César [HerausgeberIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| ISBN: |
|---|
| BKL: | |
|---|---|
| Themen: |
Antiviral agents |
| Umfang: |
1 Online-Ressource (xvii, 290 Seiten) ; Illustrationen |
|---|
| doi: |
10.1039/9781788016858 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1695623983 |
|---|
| LEADER | 01000cam a2200265 4500 | ||
|---|---|---|---|
| 001 | 1695623983 | ||
| 003 | DE-627 | ||
| 005 | 20240423215445.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200422s2022 xxk|||||o 00| ||eng c | ||
| 020 | |a 9781788016858 |c pdf |9 978-1-78801-685-8 | ||
| 020 | |a 9781839160530 |c epub |9 978-1-83916-053-0 | ||
| 024 | 7 | |a 10.1039/9781788016858 |2 doi | |
| 035 | |a (DE-627)1695623983 | ||
| 035 | |a (DE-599)KXP1695623983 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 044 | |c XA-GB | ||
| 050 | 0 | |a RM411 | |
| 084 | |a 58.28 |2 bkl | ||
| 084 | |a 44.75 |2 bkl | ||
| 245 | 1 | 0 | |a Antiviral discovery for highly pathogenic emerging viruses |c edited by César Muñoz-Fontela and Rafael Delgado |
| 264 | 1 | |a Cambridge |b Royal Society of Chemistry |c [2022] | |
| 264 | 4 | |c © 2022 | |
| 300 | |a 1 Online-Ressource (xvii, 290 Seiten) |b Illustrationen | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Drug discovery series |v 80 | |
| 520 | |a New antiviral drugs are urgently needed. Recent outbreaks caused by viruses with great epidemiological impact such as Zika, or extraordinary virulence such as Ebola, Nipah, Lassa, Crimean-Congo haemorrhagic fever highlight the current lack of clinically proven vaccines and treatments for these potentially catastrophic agents. Antiviral Discovery for Highly Pathogenic Emerging Viruses comprehensively outlines the state of the art in antiviral drug discovery including identification of targets, screening strategies and the current pipeline of antiviral candidates including regulatory issues. The book also addresses the challenges faced in proceeding from pre-clinical studies to animal models and clinical trials with these highly pathogenic agents. Ideal for drug discovery scientists and medicinal chemists with an interest in antiviral drug discovery and development, this book provides a complete overview of the latest progress in the field, recent advances and the challenges that remain in developing these highly pathogenic agents. Illustrated throughout with case studies this book is a valuable resource in this complex and multidisciplinary field | ||
| 650 | 0 | |a Antiviral agents |2 DLC | |
| 650 | 0 | |a Drug development |2 DLC | |
| 689 | 0 | 0 | |D s |0 (DE-588)4003120-2 |0 (DE-627)106390600 |0 (DE-576)208850341 |a Arzneimittelforschung |2 gnd |
| 689 | 0 | 1 | |D s |0 (DE-588)4139555-4 |0 (DE-627)104248289 |0 (DE-576)20969534X |a Viruzid |2 gnd |
| 689 | 0 | |5 (DE-627) | |
| 700 | 1 | |a Muñoz-Fontela, César |e herausgeberin |4 edt | |
| 700 | 1 | |a Delgado, Rafael |e herausgeberin |4 edt | |
| 776 | 1 | |z 9781788015646 | |
| 830 | 0 | |a RSC drug discovery series |v 80 |9 80 |w (DE-627)798562390 |w (DE-576)415648688 |w (DE-600)2787941-0 |x 2041-3211 |7 ns | |
| 856 | 4 | 0 | |u https://doi.org/10.1039/9781788016858 |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 2 | |u https://www.gbv.de/dms/bowker/toc/9781788015646.pdf |v 2022-07-28 |x Aggregator |3 Inhaltsverzeichnis |
| 912 | |a ZDB-1-RSEK |b 2021 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a ISIL_DE-28 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a ISIL_DE-3 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a ISIL_DE-89 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a ISIL_DE-21 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a ISIL_DE-291-415 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a ISIL_DE-90 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a ISIL_DE-105 | ||
| 935 | |i LOC-2024-04-23 | ||
| 936 | b | k | |a 58.28 |j Pharmazeutische Technologie |0 (DE-627)106417622 |
| 936 | b | k | |a 44.75 |j Infektionskrankheiten |j parasitäre Krankheiten |x Medizin |0 (DE-627)106415948 |
| 951 | |a BO | ||
| 980 | |2 62 |1 01 |x 0028 |b 4018378092 |h OLR-RSEK |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Die Weitergabe an Dritte sowie systematisches Downloaden sind untersagt. |y z |z 09-12-21 | ||
| 980 | |2 65 |1 01 |x 0003 |b 4030220916 |h ULBH-RSC |k Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y k3o |z 05-01-22 | ||
| 980 | |2 70 |1 01 |x 0089 |b 4019453985 |h OLR-AL-RSE |k Campusweiter Zugriff (Universität Hannover).- Vervielfältigungen (z.B. Kopien, Downloads) sind nur von einzelnen Kapiteln oder Seiten und nur zum eigenen wissenschaftlichen Gebrauch erlaubt. Keine Weitergabe an Dritte. Kein systematisches Downloaden durch Robots. |y z |z 13-12-21 | ||
| 980 | |2 2001 |1 01 |x DE-21 |b 4017744621 |c 00 |f --%%-- |d --%%-- |e --%%-- |j kp |y l01 |z 09-12-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 4017783996 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Universitätslizenz. - Der Online-Zugriff auf die "RSC eBook Collection 2021" wird im Rahmen eines Nationalkonsortiums bereitgestellt und durch die Technische Informationsbibliothek Hannover (TIB) organisiert. |y l01 |z 09-12-21 | ||
| 980 | |2 2005 |1 05 |x DE-291-415 |b 4209702080 |c 00 |f --%%-- |d e-book |e --%%-- |j n |y l05 |z 11-11-22 | ||
| 980 | |2 2014 |1 01 |x DE-90 |b 4209701769 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 11-11-22 | ||
| 980 | |2 2027 |1 01 |x DE-105 |b 4209773085 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k RSC-eBook-Collection-2021 |y l01 |z 11-11-22 | ||
| 981 | |2 62 |1 01 |x 0028 |r https://doi.org/10.1039/9781788016858 | ||
| 981 | |2 65 |1 01 |x 0003 |r https://doi.org/10.1039/9781788016858 | ||
| 981 | |2 2001 |1 01 |x DE-21 |r https://doi.org/10.1039/9781788016858 | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.redi-bw.de/start/unifr/RSC-ebooks/10.1039/9781788016858 | ||
| 981 | |2 2005 |1 05 |x DE-291-415 |r https://doi.org/10.1039/9781788016858 | ||
| 981 | |2 2014 |1 01 |x DE-90 |y Zugang im Netz des KIT |r https://doi.org/10.1039/9781788016858 | ||
| 982 | |2 2001 |1 01 |x DE-21 |8 00 |s s |a eBook-RSC-eBook-Collection-2021 | ||
| 982 | |2 2027 |1 01 |x DE-105 |8 00 |s s |a ebook | ||
| 995 | |2 62 |1 01 |x 0028 |a OLR-RSEK | ||
| 995 | |2 65 |1 01 |x 0003 |a ULBH-RSC | ||
| 995 | |2 70 |1 01 |x 0089 |a OLR-AL-RSE | ||
| 995 | |2 70 |1 01 |x 0089 |a ACQ | ||
| 998 | |2 2001 |1 01 |x DE-21 |0 2112 |f 44 | ||
| 998 | |2 2003 |1 01 |x DE-25 |0 2149 |f 15 | ||